Core Insights - Baxter International Inc. is considered one of the top cheap stocks under $20, with a current price target of $19.00 set by Wells Fargo analyst Larry Biegelsen, who maintains a Hold rating on the stock [1] - Recent data from a collaboration with The University of Texas Medical Branch indicates that the integration of smart infusion pumps with hospital electronic medical records has positively impacted clinician productivity, patient safety, and programming compliance [1][2] - Morgan Stanley analyst Patrick Wood has reduced the price target for Baxter to $15 from $19 while maintaining an Underweight rating, citing a solid industry setup for MedTech going into 2026 [3] Company Overview - Baxter International Inc. offers a diverse portfolio of essential healthcare products, including parenteral nutrition therapies, dialysis therapies, inhaled anesthetics, generic injectable pharmaceuticals, sterile IV solutions, infusion systems, surgical products, patient monitoring technologies, and respiratory health devices [4] - The company's operations are segmented into regions: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom [4] Market Position - The findings from the smart pump EMR integration study suggest a reduction in patient safety alerts and programming time, highlighting the potential of connected infusion therapy to enhance patient safety and alleviate clinician burnout [2] - Analysts believe that the MedTech sector is well-positioned for growth, supported by major product cycles and favorable hospital spending environments [3]